Karyopharm Q2 Loss Widens to $67M; Cash Runs Out in September
KPTI is trading near its 52-week low of $1.8 (15% above the low).
Summary
Karyopharm's Q2 2026 loss widened to $67 million, and the company now has cash only into September 2026, with substantial debt payments due that month. The filing reiterates substantial doubt about its ability to continue as a going concern.
Updates
· Reuters — Q2 revenue declined year-over-year as license revenue dropped, while U.S. XPOVIO net product revenue held steady at $30.8M. The company reaffirmed 2026 total revenue guidance of $130M-$150M.
Key Events · Earnings and Guidance · KPTI
-
Q2 Net Loss Widens to $67M
Net loss for the three months ended June 30, 2026 was $67.0 million, up from $37.3 million in the prior-year quarter, driven by a $32.1 million non-cash charge from fair value remeasurement of embedded derivatives and liability-classified warrants.
-
Cash Runway Ends in September
The company expects existing liquidity to fund operations only into September 2026. A $15.8 million principal payment is due September 10, 2026, and $10.1 million in interest is due September 30, 2026, which would breach the minimum liquidity covenant without new financing.
-
Going Concern Warning Reiterated
Management concluded there is substantial doubt about the company's ability to continue as a going concern within one year. Absent additional funding or a strategic transaction, the company may seek bankruptcy protection or liquidate.
-
Financing Activities in H1 2026
During the six months ended June 30, 2026, the company raised $19.8 million net from ATM sales and $26.9 million net from a private placement with RA Capital, but these funds were insufficient to extend the runway beyond September.
Analysis · KPTI · Life Sciences
The second-quarter results confirm a deteriorating financial position. A $32.1 million non-cash charge from warrant and derivative remeasurements drove the company to a $67.0 million loss for the quarter, and its cash runway now extends only into September 2026. With a $15.8 million principal payment due September 10 and $10.1 million in interest due September 30, the company faces imminent default unless it secures new financing or a strategic alternative. The going concern warning is explicit: absent additional funding, bankruptcy or liquidation is likely. This is a critical update for investors.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPTI was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46M. The 52-week trading range was $1.80 to $10.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.